Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Mansour Alfayez et al.|Cancer Discovery|2018Cited by 570
The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Naval Daver, Sreyashi Basu et al.|Cancer|2018Cited by 339